Tag: Janssen

Genmab, Janssen Biotech Entered into Exclusive Worldwide License and Option Agreement

janssen
Genmab A/S announced it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a next-generation human CD...

J&J Published Data from Phase 3 DARZALEX® Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...

Actelion Presented Latest Post-Hoc Analysis from the GRIPHON Study

janssen
Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has presented results of a post-hoc exploratory analysis of the GRIPHON study in patients with pulmo...

Janssen and Australian Institute Collaborate to Prevent PPH

Janssen Pharmaceutica N.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a sponsored research agreement with the Monash Institute of Pharmace...

FDA Approved Janssen Nasal Spray for Depression Treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved SPRAVATO™ (esketamine) CIII nasal spray for use in conjunction wi...

Janssen Got FDA Approval

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press, a single-dose, patient-controlled inject...

Morphic and Janssen in R&D Partnership

Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janss...

FDA Advisory Committee Voted For Janssen Depression Drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Manage...

Janssen and MeiraGTx to Work on Inherited Retinal Diseases

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc, a clinical-stage gene therapy company, to deve...

Philogen and Janssen Discover New Molecular Therapy

Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Jans...

Janssen Has EC Approval for nmCRPC Drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has secured marketing approval from the European Commission (EC) for Erleada (apalutamide) to treat non-metastatic castration-resistant pr...

Janssen and Locus Unite for Bacterial Infections Treatment

Janssen Pharmaceuticals has signed an exclusive collaboration and licence agreement with biotechnology firm Locus Biosciences for CRISPR products intended to treat bacterial infections. The partner...

The Oxford Science Park is to house the Vaccines Manufacturing Innovation Centre

Pharma companies are industrial partners of Britain's first facility dedicated to innovation in vaccines manufacturing. Located on a new plot close to the Magdalen Centre, home to many SMEs, the £6...

Aro Biotherapeutics receives funding to develop its protein drug platform

drug-development
Aro Biotherapeutics, a newly established biotechnology company, has raised $13 million in start-up investment to develop and commercialize Centyrins, an innovative protein drug platform.

Janssen signs collaboration and license agreement with Dutch biotech

drug discovery
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies announced an exclusive agreement with Janssen.

Korean pharma company Yuhan signs licensing deal with Janssen

cancer-diagnostics
Yuhan Corporation entered into a licensing agreement with Janssen Biotech to develop Lazertinib, a treatment for non-small cell lung cancer (NSCLC) that is undergoing clinical trials in Korea.